Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Following SURMOUNT-1, the SURMOUNT-2 trial focused on individuals who had both obesity and type 2 diabetes
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Start your journey with a consultation about how semaglutide or tirzepatide fits into your conception timeline
This $298 test helps describe the pathway-level variants involved
Among the cohort, 49% were prescribed dulaglutide (Trulicity, Eli Lilly) in 2020, which was the most prescribed GLP-1 receptor agonist during the study, according to researchers
US$ 24.51
US$ 23.68
US$ 20.64
